|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
70,650,000 |
Market
Cap: |
3.28(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.62 - $89.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
22,948 |
163,087 |
338,087 |
Total Sell Value |
$0 |
$1,362,031 |
$11,023,312 |
$20,394,162 |
Total People Sold |
0 |
2 |
4 |
4 |
Total Sell Transactions |
0 |
2 |
13 |
20 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Emster Kurt Von |
Director |
|
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
2,545,814 |
2,545,814 |
|
- |
|
Lundberg Sven Ante |
Chief Scientific Officer |
|
2016-10-24 |
4 |
B |
$14.00 |
$5,600 |
I/I |
400 |
505,617 |
1.99 |
- |
|
Lundberg Sven Ante |
Chief Scientific Officer |
|
2016-10-24 |
4 |
A |
$0.00 |
$0 |
D/D |
55,217 |
505,217 |
|
- |
|
Versant Venture Capital V (canada), Lp |
10% Owner |
|
2016-10-24 |
4/A |
A |
$0.00 |
$0 |
I/I |
6,508,699 |
79,478 |
|
- |
|
Versant Venture Capital V (canada), Lp |
10% Owner |
|
2016-10-24 |
4/A |
B |
$14.00 |
$2,254,000 |
I/I |
161,000 |
185,987 |
1.5 |
- |
|
Woiwode Thomas |
Director |
|
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
6,508,699 |
79,478 |
|
- |
|
Woiwode Thomas |
Director |
|
2016-10-24 |
4 |
B |
$14.00 |
$2,254,000 |
I/I |
161,000 |
185,987 |
2.1 |
- |
|
Bolzon Bradley J Phd |
Director |
|
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
6,508,699 |
79,478 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2016-10-24 |
4 |
B |
$14.00 |
$2,254,000 |
I/I |
161,000 |
185,987 |
2.1 |
- |
|
Celgene Corp /de/ |
10% Owner |
|
2016-10-24 |
4/A |
B |
$14.00 |
$11,202,100 |
I/I |
800,150 |
4,834,980 |
1.5 |
- |
|
Celgene Corp /de/ |
10% Owner |
|
2016-10-24 |
4/A |
A |
$0.00 |
$0 |
I/I |
4,034,830 |
4,034,830 |
|
- |
|
Versant Venture Capital V (canada), Lp |
10% Owner |
|
2016-10-24 |
4 |
A |
$14.00 |
$2,254,000 |
I/I |
161,000 |
185,987 |
|
- |
|
Coles N Anthony |
Director |
|
2016-10-24 |
4 |
A |
$14.00 |
$980,000 |
I/I |
70,000 |
70,000 |
|
- |
|
Glaxosmithkline Plc |
10% Owner |
|
2016-10-24 |
4 |
B |
$14.00 |
$931,000 |
I/I |
66,500 |
3,220,627 |
1.5 |
- |
|
Glaxosmithkline Plc |
10% Owner |
|
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
3,154,127 |
3,154,127 |
|
- |
|
George Simeon |
Director |
|
2016-10-24 |
4 |
B |
$14.00 |
$931,000 |
I/I |
66,500 |
3,220,627 |
2.1 |
- |
|
George Simeon |
Director |
|
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
3,154,127 |
3,154,127 |
|
- |
|
Celgene Corp /de/ |
10% Owner |
|
2016-10-24 |
4 |
B |
$14.00 |
$11,202,100 |
D/D |
800,150 |
4,834,980 |
2.45 |
- |
|
Celgene Corp /de/ |
10% Owner |
|
2016-10-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,034,830 |
4,034,830 |
|
- |
|
Hadley Harbor Master Investors (cayman) L.p. |
10% Owner |
|
2016-10-24 |
4 |
A |
$0.00 |
$0 |
D/D |
744,380 |
744,380 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2016-10-18 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
923,662 |
|
- |
|
Woiwode Thomas |
Director |
|
2016-10-18 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
923,662 |
|
- |
|
Bayer Aktiengesellschaft |
10% Owner |
|
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,105,330 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
239,648 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
342,007 |
|
- |
|
483 Records found
|
|
Page 19 of 20 |
|
|